Skip to main content

Market Overview

Collins Stewart: Palifosfamide P2 OS Data Bodes Well for P3

Share:

According to a research report published today by Collins Stewart, Ziopharm Oncology's (NASDAQ: ZIOP) palifosfamide endured a positive interim OS trend.

Collins Stewart reported, “Final OS data is expected at a medical meeting in 2H12. While we continue to believe the ongoing P3 PICASSO-3 study has a high likelihood of hitting its PFS co-primary endpoint in 2H12, given positive P2 PFS data (trial stopped early on a 3.4 month PFS benefit), we now have increased confidence on the OS co-primary endpoint (expected in ~2015; however, PFS will support accelerated approval in ~2014) following today's data, particularly since the P2 study was not powered to demonstrate an OS benefit. We believe palifosfamide in mSTS represents a peak U.S./E.U. opportunity of $300M+ in 2019 and look for ZIOP shares to trade higher into P3 PICASSO-3 data in 2H12.”

Collins Stewart maintains its Buy rating and $9 PT on Ziopharm Oncology, which closed Friday at $5.28.

 

Related Articles (ZIOP)

View Comments and Join the Discussion!

Posted-In: Collins StewartAnalyst Color Reiteration Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com